Top 10 traits to look for in a CDMO partner for cell, gene, or advanced therapy medicinal products


When outsourcing cell and gene therapy (CGT) or advanced therapy medicinal product (ATMP) manufacturing, the need to understand potential risks and choose a partner carefully is amplified.

This guide can help ease the CDMO selection process by identifying key areas of conflict and uncertainty in the partnership and production process. By proactively asking questions and addressing concerns with CDMO candidates, pharmaceutical companies can minimize conflicts down the line and ensure they have selected a partner that maximizes their chance of success.